Gossamer Bio
GOSS
139 hedge funds and large institutions have $520M invested in Gossamer Bio in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 41 reducing their positions, and 17 closing their positions.
173% more call options, than puts
Call options by funds: $13M | Put options by funds: $4.76M
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
19% more capital inflows, than outflows
Capital inflows: $49.3M | Capital outflows: $41.6M
12% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 41
6% more funds holding
Funds holding: 131 → 139 (+8)
1.38% more ownership
Funds ownership: 76.92% → 78.3% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Octagon Capital Advisors
New York
|
+$10.1M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$7.87M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.44M |
| 4 |
Eversept Partners
New York
|
+$3.23M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$7.72M |
| 2 |
Woodline Partners
San Francisco,
California
|
-$6.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.41M |
| 4 |
Ikarian Capital
Dallas,
Texas
|
-$3.78M |
| 5 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$3.34M |
GOSS Hedge Fund Activity: Q1 2022 in Review
139 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q1 2022, worth a combined $520M — down 22% from $665M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new GOSS positions and 17 closed out — a net gain of 8 holders — while 46 added to existing stakes and 41 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $10.1M. The largest seller was OrbiMed, exiting entirely with an estimated $7.72M sold.
- 139 institutional investors held Gossamer Bio (GOSS) as of Q1 2022, up from 131 in Q4 2021.
- Funds reported $520M of Gossamer Bio stock for Q1 2022, down 22% quarter-over-quarter.
- 25 funds opened new Gossamer Bio positions in Q1 2022 and 17 closed out, a net change of +8 holders.
- The largest Gossamer Bio buyer in Q1 2022 was Octagon Capital Advisors, an estimated $10.1M added.
- The largest Gossamer Bio seller in Q1 2022 was OrbiMed, an estimated $7.72M sold.
Based on aggregated 13F filings for Q1 2022.